imvaccine.com Contact Person: Marc Mansour, PhD Vice President, R&D Contact Information: 1721 Lower Water Street Halifax, Nova Scotia B3J 1S5 Phone: 902.492.1819 Fax: 902.421.2733 email

Immunovaccine is a clinical stage biotechnology company developing high potential vaccines for human health.  Immunovaccine's unique patented vaccine delivery and enhancement technology, the DepoVax™ platform, has achieved exciting results and positive pre-clinical safety data.  Immunovaccine's technology has attracted multiple partnerships and generated revenues through two licenses of its technology to Pfizer Animal Health.

The company's most advanced product is DPX-0907, a therapeutic vaccine against ovarian, breast and prostate cancer that, in conjunction with its vaccine delivery technology, is being readied to enter Phase 1 human clinical trials.  Immunovaccine will pursue a fast-track regulatory strategy by taking the product through a short Phase 1 into a Phase 2 clinical trial.  In addition, Immunovaccine is conducting proof of concept and pre-clinical studies for infectious disease vaccines: Pseudomonas aeruginosa, single dose pandemic influenza and Hepatitis B.